CHF Solutions Continues Physician-Led Webinar Series with Focus on Treatment of Fluid Overload in Pediatric Patients
Clinically important observations made by
- In pediatric patients, fluid overload is a common problem impacting morbidity and mortality, and fluid overload is associated with multiple conditions, such as heart surgery, nephrotic syndrome, congenital heart disease, kidney disease, solid organ and bone marrow transplants, sepsis and severe burns.
- Addressing fluid overload and initiating treatment early optimizes outcomes in pediatric patients; therefore, fluid volume should be reported and monitored as a critical vital sign, similar to other vital signs.
- To assess fluid overload, fluid volume status should be considered in light of the phases of therapy: rescue, optimization, stabilization and de-escalation.
- Treatment options for fluid overload include medical management, fluid restriction and diuretics and ultrafiltration (aquapheresis).
- While a majority of ICU patients receive diuretics to treat fluid overload, multiple studies have shown limited direct improvement in clinical outcomes.1
- Ultrafiltration provides an early alternative therapy to be considered when medical management fails to achieve fluid balance. Repeating traditional therapies may harm the patient.
- Alternative fluid removal therapies include peritoneal dialysis, continuous renal replacement therapy (CRRT), intermittent hemodialysis and ultrafiltration. Each therapy has advantages depending on the condition and treatment goals for the patient.
- Ultrafiltration with the Aquadex system is simple, easy to set up and provides flexibility to address the needs of the patient.
- In a retrospective, multi-center study, 32 critically ill pediatric patients weighing over 20 kgs and predominantly suffering from hypervolemia were treated with the Aquadex FlexFlow System and 97% (31/32) survived to the end of therapy with minimal complications associated with the system.2
“Ultrafiltration is a safe and effective therapy for removing fluid in pediatric patients weighing more than 20 kg,” said
“Since the FDA clearance of the Aquadex SmartFlow for eligible pediatric patients, pediatric hospitals across the country have recognized the benefit of utilizing gentle ultrafiltration in these patients,” said
The replay of the webinar is available at https://ir.chf-solutions.com/events and https://www.youtube.com/watch?v=sMIF5x5qqvY
About Fluid Overload in Pediatric Patients
Fluid overload (hypervolemia), which occurs when there is too much fluid in the body, is a major issue among critically ill children and adults, and when left untreated, it can lead to life-threatening consequences. Available therapies require very high relative extracorporeal blood volumes, which can be challenging for pediatric patients. In a retrospective, multi-center study, 32 critically ill pediatric patients weighing over 20 kgs and predominantly suffering from hypervolemia were treated with the Aquadex FlexFlow System and 97% (31/32) survived to the end of therapy.2
About the Aquadex SmartFlow System
The Aquadex SmartFlow system delivers clinically proven therapy using a simple, flexible and smart method of removing excess fluid from patients suffering from hypervolemia (fluid overload). The Aquadex SmartFlow system is indicated for temporary (up to 8 hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kg or more whose fluid overload is unresponsive to medical management, including diuretics. All treatments must be administered by a health care provider, within an outpatient or inpatient clinical setting, under physician prescription, both having received training in extracorporeal therapies.
About
Forward-Looking Statements
Certain statements in this release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements about the clinical outcomes associated with the treatment of fluid overload in pediatric patients. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, the risks associated with our expectations regarding the potential impacts of the COVID-19 pandemic on our business operations, the risks associated with our ability to execute on our commercial strategy, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the
CONTACTS INVESTORS:Claudia Napal Drayton Chief Financial Officer,CHF Solutions, Inc. 952-345-4205 ir@chf-solutions.com MEDIA:Jessica Stebing Health+Commerce 260-336-6202 jstebing@healthandcommerce.com
Source: CHF Solutions, Inc.